SPECIAL NOTICE
A -- TECHNOLOGY/BUSINESS OPPORTUNITY Real-Time Individualized Monitoring and Evaluation of Drug Therapy
- Notice Date
- 7/8/2008
- Notice Type
- Special Notice
- NAICS
- 238990
— All Other Specialty Trade Contractors
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue, L-795, Livermore, California, 94550
- ZIP Code
- 94550
- Solicitation Number
- FBO189-08
- Response Due
- 8/8/2008
- Archive Date
- 8/9/2008
- Point of Contact
- Connie L Pitcock, Phone: 925-422-1072
- E-Mail Address
-
pitcock1@llnl.gov
- Small Business Set-Aside
- N/A
- Description
- TECHNOLOGY/BUSINESS OPPORTUNITY Real-Time Individualized Monitoring and Evaluation of Drug Therapy Opportunity : Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract with the U.S. Department of Energy (DOE), is offering the opportunity to license a technology covering real-time individualized therapy evaluation. Background : Today, there are a limited number of tests available to detect individual variations that provide insight as to how one might respond to cancer treatment. Accelerator Mass Spectrometry (AMS) enables the study of drug metabolism and toxicity in cancer patients by allowing direct quantitation of cellular uptake and drug-DNA damage of a minute quantity of labeled drug present in blood, tissue and DNA samples. The isotopic label is radioactive, but the amount needed for AMS tracing results in a radiation dose that is less than that of a chest X-ray. This work is significant because it could answer questions including appropriate drug choice and dose concentration decisions prior to initiation of toxic chemotherapy. Description : The invention covers a method of therapy evaluation made possible by a key technological innovation: ultrasensitive detection of 14 C-labeled compounds by AMS. One may quantify drug accumulation in cells with AMS by administering isotope-labeled drugs. Isotopes may be analyzed using other methods as well. The sensitivity of AMS allows administration of low concentration of drugs so that the effect is nontoxic. The action or effect of a drug is dependent upon the specific interaction of the drug with a molecular target in the body. It is believed that the intensity of the action relies on the amount of drug reaching the target molecule. The amount of drug that reaches the target molecule is related to dosage, absorption, distribution, biotransformation and excretion. This method will take into account the time versus drug concentration response to ensure the correct amount of active drug is present to do the work. It is envisioned that the methodology be coupled to pharmacokinetic modeling so that a test dose may be applied to an individual and used to establish the optimal dose and dosing interval to attain the required drug concentration at the target site and to assess when drug resistance has developed based on changes in the kinetics of drug metabolism. This invention will allow for characterization of cellular drug uptake, which several studies have shown to be correlated to patient outcome such as tumor shrinkage and mortality. Advantages : · Dosing options : Currently, the dosage of medication is a standard dose or based on factors such as weight and age that may have no bearing on the drug's efficacy. A standard dose may prove toxic to one person because of differences in metabolism. Additionally, information yielded from this technology may assist in predicting one's response to a medication and whether the treatment will cause a tumor to shrink or whether one is becoming resistant to the drug. · Lower healthcare costs : Proper choice and dosing of medication will reduce drug costs. Additionally, this technology will enable doctors and clinicians in identifying the most efficient drug as opposed to trying multiple drugs, which may be very costly. Personalized medicine may also reduce hospitalizations from adverse reactions to drugs. Potential Applications : Utilizing LLNL's invention will enable one to tailor drug dose and dosing interval for cancer chemotherapy and promote the advent of personalized medicine. Additionally, this method's targeted use is to address three therapeutic situations: (1) To phenotype an individual for drug metabolism and use this phenotype to set the optimal drug, drug dosage and dosing interval to attain and maintain therapeutic levels in a tumor; (2) To detect as early as possible when a tumor becomes resistant to the selected drug so that drug therapy can be changed as early as possible following development of resistance, and; (3) To research and discover key genes involved in drug metabolism. Development Status: Currently we have promising results in cell culture and mice that show highly resistant cancer cells accumulate less drug compared to highly sensitive cells. Clinical studies are currently planned to start in the next year. Additionally, LLNL has filed a patent application on the technology. LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information. Please visit the IPO website at http://ipo.llnl.gov/workwithus/partneringprocess.php for more information on working with LLNL and the industrial partnering and technology transfer process. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's Accelerator Mass Spectrometry technology for personalized medicine should provide a written statement of interest, which includes the following: 1. Company Name and address. 2. The name, address, and telephone number of a point of contact. 3. A description of corporate expertise and facilities relevant to commercializing this technology.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=0e50098d7558b66df537e4ce7cbc0969&tab=core&_cview=1)
- Record
- SN01609003-W 20080710/080708221539-0e50098d7558b66df537e4ce7cbc0969 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |